RaviVijMDMBA

Oncology • Saint Louis, MO

Hematologic Oncology

PROFESSOR OF MEDICINE, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

Join to view full profile

Dr. Vij is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vij's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 314-454-8304

Fax+1 314-454-5902

Education & Training

George Washington UniversityMBA, Business administration, 2011 - 2013
Washington University in St. Louis School of Medicine2000
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1999
Rush University Medical CenterResidency, Internal Medicine, 1996
Maulana Azad Medical CollegeClass of 1990

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 1996 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission Start of enrollment: 2004 Jan 01
Completed
Phase 2
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma Start of enrollment: 2005 Sep 01
Terminated
Phase 2
Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant Start of enrollment: 2004 Jun 01
Terminated
Phase 3
A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2005 Mar 01
Terminated
Phase 2
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes Start of enrollment: 2006 Aug 01
Completed
Phase 2
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma Start of enrollment: 2007 Jan 01
Completed
Phase 2
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2007 Mar 01
Completed
Phase 2
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma Start of enrollment: 2006 Oct 01
Completed
Phase 1
Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities Start of enrollment: 2007 Feb 01
Completed
Phase 2
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation Start of enrollment: 2007 Nov 01
Terminated
Phase 2
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia Start of enrollment: 2008 May 01
Completed
Phase 1
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Start of enrollment: 2008 Jun 01
Completed
Phase 1, Phase 2
Oral Clofarabine for Acute Myeloid Leukemia Start of enrollment: 2009 Jan 01
Completed
Phase 1
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma Start of enrollment: 2008 Nov 01
Completed
Phase 1, Phase 2
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma Start of enrollment: 2008 Aug 01
Completed
Phase 2
CC-4047 (Pomalidomide) for Graft vs. Host Disease Start of enrollment: 2009 Feb 01
Completed
Phase 2
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease Start of enrollment: 2010 Oct 01
Completed
Phase 1
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
ACTIVE_NOT_RECRUITING
PHASE2
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia Start of enrollment: 2011 Feb 01
Completed
Phase 1, Phase 2
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant Start of enrollment: 2009 Dec 01
Completed
Phase 1
Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) Start of enrollment: 2010 May 01
Completed
Phase 1
Azacitidine and Lenalidomide for Acute Myeloid Leukemia Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy Start of enrollment: 2010 Jan 01
Terminated
Phase 1, Phase 2
Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant Start of enrollment: 2010 Apr 29
Completed
Phase 1
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2010 Feb 01
Completed
Phase 2
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) Start of enrollment: 2010 May 01
Terminated
Phase 1
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma Start of enrollment: 2009 Sep 01
Completed
Phase 1, Phase 2
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2010 Feb 01
Completed
Phase 1, Phase 2
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) Start of enrollment: 2010 Sep 02
Completed
Phase 1
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia Start of enrollment: 2010 Oct 01
Completed
Phase 1
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors Start of enrollment: 2011 Apr 01
Completed
Phase 2
Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML Start of enrollment: 2010 Nov 01
Completed
Phase 1
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Start of enrollment: 2010 Jul 15
Completed
Phase 2
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 May 14
Completed
Phase 1, Phase 2
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents Start of enrollment: 2011 Jun 01
Completed
Phase 2
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia Start of enrollment: 2011 Jul 01
Completed
Early Phase 1
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma Start of enrollment: 2012 Jun 01
Terminated
Early Phase 1
Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation Start of enrollment: 2012 Sep 01
Terminated
Phase 2
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation Start of enrollment: 2013 Feb 25
Completed
Phase 1
Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
Completed
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Start of enrollment: 2013 Apr 15
Terminated
Phase 1, Phase 2
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Falls Risk Questionnaire in Older Adults With Cancer Start of enrollment: 2014 Aug 01
Completed
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies Start of enrollment: 2014 Aug 25
Terminated
Phase 1
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma Start of enrollment: 2015 Jan 20
ACTIVE_NOT_RECRUITING
PHASE2
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement Start of enrollment: 2016 Sep 01
Active, not recruiting
Phase 2
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma Start of enrollment: 2017 Nov 22
ACTIVE_NOT_RECRUITING
PHASE2
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma Start of enrollment: 2020 Apr 03
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States.
Malin Hultcrantz, David Kleinman, Ravi Vij, Fernando Escalante, Michel Delforge
Haematologica. 2025-03-01
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.
Marlise R Luskin, Jun Yin, Gerard Lozanski, Emily Curran, Gregory Malnassy
Cancer. 2025-02-15
Germline predisposition in multiple myeloma.
Fernanda Martins Rodrigues, Jagoda Jasielec, Melody Perpich, Aelin Kim, Luke Moma
Iscience. 2025-01-17

Journal Articles

Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Ravi Vij, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Practical Use of Imaging From MGUS to Myeloma
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Investigational Drug May Improve Stem Cell Transplantation for Multiple Myeloma PatientsApril 17th, 2023
Karyopharm’s Selinexor Combination for Multiple Myeloma Unlikely to See Second-Line Use Despite Likely FDA ApprovalDecember 18th, 2020
Vij Highlights Benefits of Quadruplet Therapy for Patients with Multiple MyelomaDecember 13th, 2019
Join now to see all